RNF125 | OmnibusX

I. Expression across cell types

Name	Number of supported studies	Average coverage
natural killer cell	35 studies	31% ± 14%	Explore
CD8-positive, alpha-beta T cell	21 studies	28% ± 14%	Explore
CD4-positive, alpha-beta T cell	21 studies	26% ± 8%	Explore
T cell	18 studies	23% ± 8%	Explore
CD16-negative, CD56-bright natural killer cell, human	15 studies	35% ± 10%	Explore
CD16-positive, CD56-dim natural killer cell, human	14 studies	39% ± 13%	Explore
mature NK T cell	14 studies	28% ± 9%	Explore
gamma-delta T cell	12 studies	33% ± 12%	Explore
mucosal invariant T cell	10 studies	33% ± 15%	Explore
CD8-positive, alpha-beta memory T cell	10 studies	43% ± 22%	Explore
naive thymus-derived CD8-positive, alpha-beta T cell	9 studies	29% ± 12%	Explore
effector memory CD8-positive, alpha-beta T cell	9 studies	34% ± 14%	Explore
regulatory T cell	9 studies	33% ± 24%	Explore
naive thymus-derived CD4-positive, alpha-beta T cell	8 studies	26% ± 8%	Explore
innate lymphoid cell	7 studies	36% ± 20%	Explore
endothelial cell	5 studies	22% ± 5%	Explore
CD4-positive, alpha-beta memory T cell	5 studies	36% ± 8%	Explore
effector CD8-positive, alpha-beta T cell	4 studies	23% ± 5%	Explore
hematopoietic stem cell	4 studies	20% ± 4%	Explore
plasmacytoid dendritic cell	4 studies	19% ± 1%	Explore
effector memory CD4-positive, alpha-beta T cell	4 studies	34% ± 15%	Explore
microglial cell	4 studies	20% ± 4%	Explore
leukocyte	3 studies	23% ± 3%	Explore
conventional dendritic cell	3 studies	49% ± 29%	Explore
lymphocyte	3 studies	32% ± 6%	Explore
CD4-positive helper T cell	3 studies	52% ± 30%	Explore
dendritic cell	3 studies	47% ± 34%	Explore
macrophage	3 studies	42% ± 35%	Explore
oligodendrocyte	3 studies	22% ± 4%	Explore
T follicular helper cell	3 studies	27% ± 2%	Explore
group 3 innate lymphoid cell	3 studies	27% ± 8%	Explore
effector memory CD8-positive, alpha-beta T cell, terminally differentiated	3 studies	29% ± 4%	Explore

II. Expression across tissues

Name	Number of supported studies	Average coverage
peripheral blood	11 studies	23% ± 7%	Explore

Tissue	GTEx Coverage	GTEx Average TPM	GTEx Number of samples	TCGA Coverage	TCGA Average TPM	TCGA Number of samples
breast	100%	1974.66	459 / 459	92%	6.68	1023 / 1118
prostate	92%	384.24	226 / 245	95%	6.21	477 / 502
thymus	97%	432.26	633 / 653	90%	4.87	546 / 605
lung	100%	831.10	576 / 578	76%	4.14	875 / 1155
intestine	96%	724.48	924 / 966	78%	5.03	412 / 527
stomach	92%	344.30	330 / 359	81%	5.66	233 / 286
skin	79%	607.24	1421 / 1809	90%	10.64	427 / 472
esophagus	97%	497.06	1404 / 1445	70%	5.00	129 / 183
pancreas	85%	269.20	279 / 328	83%	4.36	147 / 178
liver	99%	854.94	224 / 226	64%	3.90	260 / 406
ovary	74%	227.28	133 / 180	73%	3.63	313 / 430
uterus	98%	587.84	167 / 170	48%	1.82	221 / 459
bladder	95%	546.62	20 / 21	51%	2.56	255 / 504
kidney	56%	165.74	50 / 89	68%	4.09	611 / 901
brain	64%	324.43	1678 / 2642	60%	2.45	422 / 705
adrenal gland	79%	221.00	204 / 258	25%	0.81	57 / 230
adipose	100%	2363.48	1204 / 1204	0%	0	0 / 0
spleen	100%	885.45	241 / 241	0%	0	0 / 0
peripheral blood	93%	811.19	862 / 929	0%	0	0 / 0
muscle	86%	347.41	688 / 803	0%	0	0 / 0
heart	82%	334.51	708 / 861	0%	0	0 / 0
blood vessel	68%	354.82	906 / 1335	0%	0	0 / 0
lymph node	0%	0	0 / 0	66%	6.62	19 / 29
tonsil	0%	0	0 / 0	62%	2.23	28 / 45
eye	0%	0	0 / 0	24%	0.89	19 / 80
abdomen	0%	0	0 / 0	0%	0	0 / 0
bone marrow	0%	0	0 / 0	0%	0	0 / 0
diaphragm	0%	0	0 / 0	0%	0	0 / 0
gingiva	0%	0	0 / 0	0%	0	0 / 0
nasal cavity	0%	0	0 / 0	0%	0	0 / 0
nasopharynx	0%	0	0 / 0	0%	0	0 / 0
nose	0%	0	0 / 0	0%	0	0 / 0
placenta	0%	0	0 / 0	0%	0	0 / 0
spinal column	0%	0	0 / 0	0%	0	0 / 0
ureter	0%	0	0 / 0	0%	0	0 / 1

III. Associated gene sets

GO_0002250	Biological process	adaptive immune response
GO_0032480	Biological process	negative regulation of type I interferon production
GO_0006511	Biological process	ubiquitin-dependent protein catabolic process
GO_1990830	Biological process	cellular response to leukemia inhibitory factor
GO_0000209	Biological process	protein polyubiquitination
GO_0039536	Biological process	negative regulation of RIG-I signaling pathway
GO_0043231	Cellular component	intracellular membrane-bounded organelle
GO_0000139	Cellular component	Golgi membrane
GO_0034098	Cellular component	VCP-NPL4-UFD1 AAA ATPase complex
GO_0061630	Molecular function	ubiquitin protein ligase activity
GO_0005515	Molecular function	protein binding
GO_0008270	Molecular function	zinc ion binding
GO_0002039	Molecular function	p53 binding
GO_0031624	Molecular function	ubiquitin conjugating enzyme binding

IV. Literature review

[source]

Gene name	RNF125
Protein name	Ring finger protein 125 E3 ubiquitin-protein ligase RNF125 (EC 2.3.2.27) (RING finger protein 125) (T-cell RING activation protein 1) (TRAC-1)
Synonyms
Description	FUNCTION: E3 ubiquitin-protein ligase that mediates ubiquitination and subsequent proteasomal degradation of target proteins, such as RIGI, MAVS/IPS1, IFIH1/MDA5, JAK1 and p53/TP53 . Acts as a negative regulator of type I interferon production by mediating ubiquitination of RIGI at 'Lys-181', leading to RIGI degradation . Mediates ubiquitination and subsequent degradation of p53/TP53 . Mediates ubiquitination and subsequent degradation of JAK1 . Acts as a positive regulator of T-cell activation . .
Accessions	ENST00000217740.4 J3QQW8 ENST00000580209.1 Q96EQ8

RNF125 report

I. Expression across cell types

II. Expression across tissues

III. Associated gene sets

IV. Literature review